NASDAQ:STROSutro Biopharma Stock Price, Forecast & News

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, STRO stock has increased by 21.3% and is now trading at $9.84. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sutro Biopharma.

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Sutro Biopharma.

Sutro Biopharma Inc (NASDAQ:STRO) issued its earnings results on Monday, May, 11th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.69) by $0.15. The business had revenue of $7.15 million for the quarter, compared to analysts' expectations of $11.16 million. Sutro Biopharma had a negative net margin of 148.06% and a negative return on equity of 59.70%. View Sutro Biopharma's earnings history.

8 analysts have issued 12 month target prices for Sutro Biopharma's shares. Their forecasts range from $16.00 to $22.00. On average, they anticipate Sutro Biopharma's share price to reach $18.67 in the next year. This suggests a possible upside of 89.7% from the stock's current price. View analysts' price targets for Sutro Biopharma.

News coverage about STRO stock has trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sutro Biopharma earned a daily sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutSutro Biopharma.

Sutro Biopharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 85,800 shares, an increase of 46.2% from the April 30th total of 58,700 shares. Based on an average daily trading volume, of 41,500 shares, the short-interest ratio is currently 2.1 days. Currently, 0.7% of the shares of the company are sold short. View Sutro Biopharma's Current Options Chain.

Some companies that are related to Sutro Biopharma include Orchard Therapeutics (ORTX), Cellectis (CLLS), Atara Biotherapeutics (ATRA), BioCryst Pharmaceuticals (BCRX), Proteon Therapeutics (PRTO), BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Adaptimmune Therapeutics (ADAP), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Vericel (VCEL), AVITA MED LTD/S (RCEL), Avrobio (AVRO) and Prevail Therapeutics (PRVL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV), Vaxart (VXRT), Aduro BioTech (ADRO), Fortress Biotech (FBIO), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV) and Protalix Biotherapeutics (PLX).

(STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Sutro Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (5.54%), BlackRock Inc. (2.84%), VV Manager LLC (2.01%), Driehaus Capital Management LLC (1.25%), State Street Corp (0.77%) and Janus Henderson Group PLC (0.72%). Company insiders that own Sutro Biopharma stock include Arturo Md Molina, Daniel H Petree, Merck & Co, Inc, Trevor Hallam and William J Newell. View institutional ownership trends for Sutro Biopharma.

STRO stock was sold by a variety of institutional investors in the last quarter, including VV Manager LLC, UBS Group AG, Pentwater Capital Management LP, Deutsche Bank AG, Spark Investment Management LLC, and JPMorgan Chase & Co.. View insider buying and selling activity for Sutro Biopharma.

STRO stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., Victory Capital Management Inc., Acadian Asset Management LLC, Eventide Asset Management LLC, Geode Capital Management LLC, BlackRock Inc., and Nuveen Asset Management LLC. Company insiders that have bought Sutro Biopharma stock in the last two years include Arturo Md Molina, Merck & Co, Inc, and William J Newell. View insider buying and selling activity for Sutro Biopharma.

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STRO stock can currently be purchased for approximately $9.84.

Sutro Biopharma has a market capitalization of $228.58 million and generates $42.74 million in revenue each year. The company earns $-55,740,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe.

The official website for Sutro Biopharma is www.sutrobio.com.

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.